Error loading player: No playable sources found

64247

Parallel Session 8: Approaches to Decentralized Manufacturing

Date
June 28, 2023
This product is not available for individual purchase, but it is available as part of the following products:
Thumbnail for CGTP Summit 2023 / Cell and Gene Therapy Products Symposium 2023
The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products…

Decentralized manufacturing involves the use of manufacturing units that can be deployed to multiple locations and in cases, to sites close to the patients. This new manufacturing concept can bring benefits over more traditional, central manufacturing, allowing, for instance, a production adaptable to demand or a more agile and flexible reaction to  public health emergencies. In the case of cell and gene therapies, many are highly personalized or have very short shelf-lives, features that could benefit from being manufactured close to the patients. 




Decentralized manufacturing presents new regulatory challenges since it requires a shift away from existing frameworks that are designed to meet the regulatory expectations for large-scale centralized manufacture. 




This session will bring together regulators and manufacturers with the objective of reviewing the different decentralized manufacturing approaches (e.g. distributed vs point of care) and identify some of the regulatory adaptations needed. The session will also discuss proposals to fulfil manufacturing and control challenges on a decentralized scenario, such as comparability between (potentially) many manufacturing sites, or carrying out complex testing (e.g. potency).




Session Speakers:




Decentralised and Point of Care Manufacturing - A UK Perspective 

Ian Rees, Retired, MHRA




Distributed Manufacturing for Cell Therapies: Regulatory Challenges and Solutions

Gülbengü Yüksel, Tigen Pharma SA




Attaining Worldwide Standardization Within A Decentralized Framework 

Chaya Mazouz, Orgenesis Inc.




Additional Panelists:




Johnny Lam, CBER, FDA

Marcos Timón, AEMPS

Related Products

Thumbnail for Parallel Session 6: Allogeneic Cell-based Therapies: Next Frontier in Advanced Therapies
Parallel Session 6: Allogeneic Cell-based Therapies: Next Frontier in Advanced Therapies
Allogeneic cell therapies have a potential to revolutionize life-saving Cell and Gene therapy (CGT) field by removing the bottlenecks created by long scheduling delays, lengthy manufacturing times and potential product failures of autologous cell therapies…
Thumbnail for Parallel Session 1: CMC Challenges with Ultra Rare Diseases
Parallel Session 1: CMC Challenges with Ultra Rare Diseases
Bringing treatment to those afflicted with an ultra-rare disease is complex. These products are encumbered with challenges ranging from high development costs with a limited ROI, to issues with executing and interpreting clinical trials with unusually small patient populations…
Thumbnail for Plenary Session 5: Challenges with Incoming Materials - Raw, Starting, Ancillary, etc.
Plenary Session 5: Challenges with Incoming Materials - Raw, Starting, Ancillary, etc.
Raw material selection decisions early in the development of ATMPs are crucial and can impact the final product quality and ultimately patient safety…